Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Prescribed Medication for Acute Treatment for Migraine Market By Drug Type, By Route of Administration, By Distribution Channel and Geography
Prescribed Medication For Acute Treatment For Migraine Market size estimated to be valued at US$ 2,587.9 million in 2023 and is poised to grow at a significant CAGR of 13.7% over 2024-2030. The market for prescribed medications for acute treatment of migraine is expected to offer lucrative opportunities for the market players due to the launch of novel molecules in the U.S. market. The companies have focused on novel therapeutics, an alternative to the triptan class of drugs due to the adverse effects like cardiovascular disorders, chest pressure, and others. Novel treatment options and increased prevalence of migraine are expected to drive the market. Increased awareness initiatives, the availability of research funds from private and public bodies, a development in the reimbursement scenario for associated medications, and increasing awareness about the effectiveness of such medicines are among the significant factors fuelling the market's growth.
Furthermore, rising pharmaceutical R&D operating costs and rising healthcare spending are expected to drive the global prescribed medications for acute migraine treatment market growth rate during the forecast period. In the prescribed medications for acute treatment of migraine market, abortive prescribed medications for acute treatment of migraine accounted for a larger revenue share in 2021 and are projected to grow with a CAGR of 13.9% from 2022-2028 to reach US$ 1,653.7 Mn by 2028. However, the market for prophylactic drugs is anticipated to grow with a significant CAGR over the forecast years in prescribed medications for acute treatment of migraine.
Study Period
2024-2030Base Year
2023CAGR
13.7%Largest Market
North AmericaFastest Growing Market
Europe
The increasing awareness of novel drug classes and the rising incidence of migraine problems worldwide drive the target market's growth. Additionally, factors such as increasing work pressure, high alcohol consumption, growing demand for quality drugs, changes in lifestyles, and awareness among patients associated with the prevention and treatment of migraine further increase the demand levels for the global prescribed medications for acute treatment of migraine market. The increasing precedence of other therapies and side effects associated with migraine drugs limit the growth of the prescribed medications for acute migraine treatment market.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 2,587.9 million |
Market CAGR |
13.7% |
By Drug Type |
|
By Route-administration |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Prescribed Medication For Acute Treatment For Migraine Market size estimated to be valued at US$ 2,587.9 million in 2022 and is poised to grow at a significant CAGR of 13.7% over 2023-2029.
Europe is the fastest-growing for Prescribed Medication For Acute Treatment For Migraine Market.
1.Executive Summary |
2.Global Prescribed Medication for Acute Treatment for Migraine Market Introduction |
2.1.Global Prescribed Medication for Acute Treatment for Migraine Market - Taxonomy |
2.2.Global Prescribed Medication for Acute Treatment for Migraine Market - Definitions |
2.2.1.Drug Type |
2.2.2.Route-administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Prescribed Medication for Acute Treatment for Migraine Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Prescribed Medication for Acute Treatment for Migraine Market Analysis, 2019-2023 and Forecast 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Prescribed Medication for Acute Treatment for Migraine Market By Drug Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Abortive |
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Prophylactic |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Prescribed Medication for Acute Treatment for Migraine Market By Route-administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Injectables |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Prescribed Medication for Acute Treatment for Migraine Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Prescribed Medication for Acute Treatment for Migraine Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Prescribed Medication for Acute Treatment for Migraine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. Drug Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Abortive |
9.1.2.Prophylactic |
9.2. Route-administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Injectables |
9.2.3.Others |
9.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Prescribed Medication for Acute Treatment for Migraine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Abortive |
10.1.2.Prophylactic |
10.2. Route-administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Injectables |
10.2.3.Others |
10.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11.Asia Pacific (APAC) Prescribed Medication for Acute Treatment for Migraine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Abortive |
11.1.2.Prophylactic |
11.2. Route-administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Injectables |
11.2.3.Others |
11.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Prescribed Medication for Acute Treatment for Migraine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Abortive |
12.1.2.Prophylactic |
12.2. Route-administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Injectables |
12.2.3.Others |
12.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Prescribed Medication for Acute Treatment for Migraine Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Abortive |
13.1.2.Prophylactic |
13.2. Route-administration Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Injectables |
13.2.3.Others |
13.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.AstraZeneca Plc. |
14.2.2.Novartis AG |
14.2.3.Merck & Co., Inc. |
14.2.4.Pfizer, Inc. |
14.2.5.Teva Pharmaceutical Industries Ltd. |
14.2.6.Endo Pharmaceuticals Inc. |
14.2.7.Avanir Pharmaceuticals, Inc. |
14.2.8.Eli Lilly and Company |
14.2.9.Biohaven Pharmaceutical Holding Co., Ltd |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players